Research & analysis · Biotech stock research
Biotech stock research: AI biotech stock analysis, pipeline review and cash runway
Enter a ticker · read the research card · you decide
AI research card
Stocks · ETFs · Crypto · StartupsEnter any ticker to see a research card
Thesis, bull and bear case, key metrics, comparables and risk flags, synthesized into one structured tear-sheet.
Sample output is illustrative. Not financial advice.
Thesis
Bull case
Bear case
Key metrics
illustrative
Comparables
Risk flags
Informational only · sample output, not live market data · not financial advice.
Most clinical-stage biotechs have no revenue, no earnings and no book value worth discounting, which makes every conventional valuation ratio undefined. What they have instead is a pipeline of drug candidates at different trial phases, a pile of cash burning at a known rate, and a schedule of readouts that will either validate the science or end the program. Research on a biotech is really an assessment of three things: what is in the pipeline, how long the cash lasts, and what happens at the next catalyst.
Investables.ai structures that assessment. Enter any US biotech ticker and it maps the pipeline candidate by candidate with indication and trial phase, calculates quarterly cash burn and the resulting runway in months, flags whether that runway extends past the next major readout or whether a financing is likely first, lists upcoming catalysts including trial data and regulatory decision dates, and summarizes partnership and licensing economics. Then it gives you the bull case, the bear case and the risk flags. It does not predict trial outcomes, because nobody can, and any tool claiming otherwise is selling you a coin flip. Informational research only.
Both sides bull and bear
Risk flags on every card
The short answer
How do you analyze a biotech stock?
Because most clinical-stage biotechs have no earnings, analysis rests on three things: the pipeline (which candidates, which indications, which trial phase), the cash runway (quarterly burn against cash on hand, and whether it reaches the next readout), and the catalyst calendar of trial data and regulatory decisions. Dilution risk matters more than valuation multiples, since a company that runs short of cash before a readout raises equity on bad terms. Investables.ai maps all three on any US biotech ticker.
Last updated July 2026
Why it works
The three questions that decide a biotech
The pipeline is the asset
A clinical-stage biotech is a portfolio of shots on goal. What matters is how many candidates there are, how advanced each one is, whether they depend on the same underlying mechanism (in which case one failure can invalidate several programs at once), and how large the addressable indication is if a drug reaches market.
Cash runway sets the terms of everything
Burn rate against cash on hand gives you a number of months. If that number does not comfortably cover the next major readout, the company will almost certainly raise equity beforehand, and it will do so from a position of weakness. Runway is often a better predictor of shareholder dilution than any clinical judgment.
Catalysts are dates, not opinions
Trial data readouts, FDA decision dates and interim analyses are scheduled events that concentrate risk into single days. Knowing what is coming and when, and whether the balance sheet can survive a bad outcome, is most of what practical biotech research consists of.
What you get
A structured first pass on every name
Enter any ticker or asset and the research card synthesizes the thesis, lays out the bull and bear case, surfaces the key metrics and comparables, and flags the risks, so your own diligence starts further along.
- Maps every pipeline candidate with indication and trial phase
- Calculates quarterly cash burn and runway in months
- Flags whether the runway reaches the next major readout
- Lists scheduled catalysts including data and decision dates
- Summarizes partnership, licensing and royalty economics
- Highlights dilution risk, concentration and mechanism overlap
Thesis
Dominant AI accelerator supplier. The debate is the durability of data-center demand versus a cyclical capex peak.
Bull
CUDA moat, near-monopoly share
Bear
Customer concentration, cycle risk
Side by side
What each clinical phase means for risk
Historical industry-wide success rates vary by therapeutic area and by study. Treat these as broad orders of magnitude, not as predictions about any single program.
| Stage | What it tests | What it means for the investment case |
|---|---|---|
| Preclinical | Laboratory and animal evidence | Optionality only; value rests almost entirely on the platform and the team |
| Phase 1 | Safety and dosing in a small group | Binary safety risk; no efficacy signal to rely on yet |
| Phase 2 | Whether the drug works, and at what dose | The single biggest attrition point, and usually the largest price move |
| Phase 3 | Efficacy confirmed at scale against a comparator | Expensive and slow, but failure here is the most damaging outcome |
| Regulatory review | Whether the FDA accepts the evidence package | Decision date is a known, dateable catalyst |
| Commercial | Whether physicians prescribe and payers reimburse | Ordinary equity analysis finally applies: revenue, margin, competition |
Informational research only. Investables.ai does not predict clinical trial outcomes or regulatory decisions, and does not recommend any security.
Why Investables.ai
One research card that compresses the reading
Not a wall of raw data, not a one-sided opinion, and not a six-figure terminal. The thesis, both sides of the argument and the risks, in one structured tear-sheet you can act on. You stay in control of every decision.
Both sides, every time
The bull case and the bear case sit side by side, so you weigh the argument instead of reading a single take. Informational only, never a recommendation.
Risks on the page
Valuation, concentration and regulatory risks are flagged explicitly, so the downside is visible up front rather than buried in a footnote.
Faster diligence
A structured first pass in seconds means you spend your time on judgement, not on gathering, across stocks, ETFs, crypto and startups.
Good questions
Questions about biotech stock research
Explore more
More ways investors research with Investables.ai
AI investment research tool
Turn any ticker into a structured research card in seconds.
Learn moreAI stock analysis
Analyze any stock end to end without the manual grind.
Learn moreAI equity research
Sell-side-style equity research, generated on demand.
Learn moreAI financial analysis
Read a company's financials at a glance.
Learn moreAI ETF analysis
See what an ETF actually holds and what drives it.
Learn moreStock fundamental analysis software
Fundamentals, ratios and quality scores on any stock.
Learn moreResearch guides
How investors run this analysis by hand
- How to Read an Earnings Report: A Step-by-Step Sequence How to read an earnings report: what is in the package, the order to read it in, why guidance moves the stock...
- What Is Free Cash Flow? Formula, Margin and How to Use It What is free cash flow, how to calculate it from the cash flow statement, what a good free cash flow margin lo...
- How to Spot a Value Trap: 7 Warning Signs Before You Buy How to spot a value trap: the warning signs that separate a cheap stock from a broken one, where traps concent...
Start your research with one structured card
Enter any ticker or asset and read the thesis, both sides of the argument and the risk flags in seconds. Built to make your own diligence faster. You decide, every time.
Informational only, not financial advice · past performance does not guarantee future results